Conv. Plasma
Nigella Sativa
Peg.. Lambda

All vitamin D studies
Meta analysis
Home COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -44% treatment Improvement Relative Risk ICU admission -5% treatment Hospitalization time -5% no CI Mortality (b) -117% levels ICU admission (b) 65% levels Progression 79% levels Vitamin D  COVID-VIT-D  LATE TREATMENT  RCT Is late treatment with vitamin D beneficial for COVID-19? RCT 543 patients in multiple countries (April 2020 - April 2021) Higher mortality with vitamin D (not stat. sig., p=0.31) Cannata-Andía et al., BMC Medicine, Feb 2022 Favors vitamin D Favors control

A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D — a randomised multicentre international clinical trial

Cannata-Andía et al., BMC Medicine, doi:10.1186/s12916-022-02290-8, COVID-VIT-D, NCT04552951
Feb 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 274 very late stage (>80% pulmonary involvement at baseline) hospitalized COVID-19 patients treated with a single dose of cholecalciferol, and 269 control patients, showing no significant differences. High serum calcidiol levels at admission were associated with lower pulmonary involvement, shorter hospitalization, and lower ICU admission.
Serum levels increased in the treatment group, however average levels were still insufficient at discharge. Calcifediol or calcitriol, which avoids several days delay in conversion, may be more successful, especially with this very late stage usage.
100,000IU cholecalciferol.
Cholecalciferol was used in this study. Meta analysis shows that late stage treatment with calcitriol / calcifediol (or paricalcitol, alfacalcidol, etc.) is more effective than cholecalciferol: 65% [41‑79%] lower risk vs. 38% [25‑49%] lower risk. Cholecalciferol requires two hydroxylation steps to become activated - first in the liver to calcifediol, then in the kidney to calcitriol. Calcitriol, paricalcitol, and alfacalcidol are active vitamin D analogs that do not require conversion. This allows them to have more rapid onset of action compared to cholecalciferol. The time delay for cholecalciferol to increase serum calcifediol levels can be 2-3 days, and the delay for converting calcifediol to active calcitriol can be up to 7 days.
This is the 11th of 27 COVID-19 RCTs for vitamin D, which collectively show efficacy with p=0.00002.
This is the 71st of 115 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 30 sextillion). This study is excluded in the after exclusion results of meta analysis: very late stage study using cholecalciferol instead of calcifediol or calcitriol.
risk of death, 44.0% higher, RR 1.44, p = 0.31, treatment 22 of 274 (8.0%), control 15 of 269 (5.6%).
risk of ICU admission, 4.9% higher, RR 1.05, p = 0.82, treatment 47 of 274 (17.2%), control 44 of 269 (16.4%).
hospitalization time, 5.3% higher, relative time 1.05, treatment 274, control 269.
risk of death, 117.0% higher, RR 2.17, p = 0.20, high D levels 87, low D levels 96, >25 vs. ≤10 ng/mL, adjusted by demographics, comorbidities, and laboratory parameters, outcome based on serum levels.
risk of ICU admission, 65.0% lower, RR 0.35, p = 0.04, high D levels 87, low D levels 96, >25 vs. ≤10 ng/mL, adjusted by demographics, comorbidities, and laboratory parameters, outcome based on serum levels.
risk of progression, 79.0% lower, RR 0.21, p = 0.003, high D levels 87, low D levels 96, pulmonary involvment at admission, >25 vs. ≤10 ng/mL, adjusted by demographics, comorbidities, and laboratory parameters, outcome based on serum levels.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cannata-Andía et al., 18 Feb 2022, Randomized Controlled Trial, multiple countries, peer-reviewed, median age 59.0, 22 authors, study period 4 April, 2020 - 22 April, 2021, dosage 100,000IU single dose, trial NCT04552951 (history) (COVID-VIT-D).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial
Jorge B Cannata-Andía, Augusto Díaz-Sottolano, Pehuén Fernández, Carmen Palomo-Antequera, Pablo Herrero-Puente, Ricardo Mouzo, Natalia Carrillo-López, Sara Panizo, Guillermo H Ibañez, Carlos A Cusumano, Carolina Ballarino, Vicente Sánchez-Polo, Jacqueline Pefaur-Penna, Irene Maderuelo-Riesco, Jesús Calviño-Varela, Mónica D Gómez, Carlos Gómez-Alonso, John Cunningham, Manuel Naves-Díaz, Walter Douthat, José L Fernández-Martín
BMC Medicine, doi:10.1186/s12916-022-02290-8
Background: Vitamin D status has been implicated in COVID-19 disease. The objective of the COVID-VIT-D trial was to investigate if an oral bolus of cholecalciferol (100,000 IU) administered at hospital admission influences the outcomes of moderate-severe COVID-19 disease. In the same cohort, the association between baseline serum calcidiol levels with the same outcomes was also analysed. Methods: The COVID-VIT-D is a multicentre, international, randomised, open label, clinical trial conducted throughout 1 year. Patients older than 18 years with moderate-severe COVID-19 disease requiring hospitalisation were included. At admission, patients were randomised 1:1 to receive a single oral bolus of cholecalciferol (n=274) or nothing (n=269). Patients were followed from admission to discharge or death. Length of hospitalisation, admission to intensive care unit (ICU) and mortality were assessed. Results: In the randomised trial, comorbidities, biomarkers, symptoms and drugs used did not differ between groups. Median serum calcidiol in the cholecalciferol and control groups were 17.0 vs. 16.1 ng/mL at admission and 29.0 vs. 16.4 ng/mL at discharge, respectively. The median length of hospitalisation (10.
Abbreviations AEMPs: Spanish Agency for Medicines and Health Products; BMI: Body mass index; CAT : Computed axial tomography; CRP: C-reactive protein; HUCA : Hospital Universitario Central de Asturias; ICU: Intensive care unit; IL-6: Interleukin 6; PCR: Polymerase chain reaction; SARS-CoV-2: Severe Acute Respiratory Syndrome CoronaVirus 2. Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s12916-022-02290-8. S1 . Variables collected in the COVID-VIT-D trial. T. Table S2 . Symptoms at discharge. Table S3 . Biochemical parameters at discharge. Table S4 . Demographic, comorbidities, and serum calcidiol categories at hospital admission. Table S5 . Relevant biochemical parameters and serum calcidiol categories at hospital admission. Table S6 . Relevant biochemical parameters and serum calcidiol categories at hospital admission in age-matched patients. Table S7 . Pulmonary involvement at admission and outcomes according to serum calcidiol categories. Table S8 . Types and number of drugs received during the hospitalization and serum calcidiol categories at hospital admission. Table S9 . Demographic, comorbidities, and serum calcidiol categories at admission in agematched patients. Table S10 . Types and number of drugs received during the hospitalization and serum calcidiol categories at hospital admission in age-matched patients. Table S11 . Relevant biochemical parameters and serum calcidiol..
Alvarez, Aguilar-Jimenez, Rugeles, The potential protective role of vitamin D supplementation on HIV-1 infection, Front Immunol
Alvarez-Hernández, Gómez-Alonso, Jb, Vitamin D supplementation: what is right?, Clin Cases Miner Bone Metab
Amrein, Parekh, Westphal, Preiser, Berghold et al., Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study), BMJ open
Asensio, Mauricio, Huca, None
Ayelign, Workneh, Molla, Role of vitamin-D supplementation in TB/HIV co-infected patients, Infect Drug Resist
Bjorkhem-Bergman, Missailidis, Karlsson-Valik, Tammelin, Ekstrom et al., Vitamin D supplementation to persistent carriers of MRSA-a randomized and placebo-controlled clinical trial, Eur J Clin Microbiol Infect Dis
Camargo, Sluyter, Stewart, Khaw, Lawes et al., Effect of monthly high-dose vitamin D supplementation on acute respiratory infections in older adults: a randomized controlled trial, Clin Infect Dis
Cannata-Andia, Gomez, Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure, Nephrol Dial Transplant
Castillo, Costa, Barrios, Diaz, Miranda et al., Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study, J Steroid Biochem Mol Biol
Chowdhury, Kunutsor, Vitezova, Oliver-Williams, Chowdhury et al., Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies, BMJ (Clinical research ed
Christakos, Dhawan, Verstuyf, Verlinden, Carmeliet, Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects, Physiol Rev
Coussens, Martineau, Wilkinson, Anti-inflammatory and antimicrobial actions of vitamin d in combating TB/HIV, Scientifica
Dusso, Molecular biology of Vitamin D: genomic and nongenomic actions of vitamin D in chronic kidney disease
Fernández-Martín, Canteros, Alles, Massari, Cannata-Andía, Aluminum exposure in chronic renal failure in iberoamerica at the end of the 1990s: overview and perspectives, Am J Med Sci
Ferrari, Daniela, Hblt, Chile, None
Gaksch, Jorde, Grimnes, Joakimsen, Schirmer et al., Vitamin D and mortality: individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium, PLoS One
Ganmaa, Enkhmaa, Nasantogtokh, Sukhbaatar, Tumur-Ochir et al., Vitamin D, respiratory infections, and chronic disease: Review of meta-analyses and randomized clinical trials, J Intern Med
Ganmaa, Uyanga, Zhou, Gantsetseg, Delgerekh et al., Vitamin D supplements for prevention of tuberculosis infection and disease, New Engl J Med
Gassen, Niemeyer, Muth, Corman, Martinelli et al., SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection, Nat Commun
Ginde, Blatchford, Breese, Zarrabi, Linnebur et al., High-dose monthly vitamin D for prevention of acute respiratory infection in older long-term care residents: a randomized clinical trial, J Am Geriatr Soc
Ginde, Brower, Caterino, Finck, Banner-Goodspeed et al., Early high-dose vitamin D(3) for critically ill, vitamin D-deficient patients, N Engl J Med
Grandi, Breitling, Vossen, Hahmann, Wüsten et al., Serum vitamin D and risk of secondary cardiovascular disease events in patients with stable coronary heart disease, Am Heart J
Grant, Review of recent advances in understanding the role of vitamin D in reducing cancer risk: breast, colorectal, prostate, and overall cancer, Anticancer Res
Haykal, Samji, Zayed, Gakhal, Dhillon et al., The role of vitamin D supplementation for primary prevention of cancer: metaanalysis of randomized controlled trials, J Community Hosp Intern Med Perspect
Heart, Institute, Ginde, Brower, Caterino et al., Early high-dose vitamin D3 for critically ill, vitamin D-deficient patients, New Engl J Med
Hernandez, Nan, Fernandez-Ayala, Garcia-Unzueta, Hernandez-Hernandez et al., Vitamin D status in hospitalized patients with SARS-CoV-2 infection, J Clin Endocrinol Metab
Holick, Vitamin, Physiology, molecular biology, and clinical applications
Hueniken, Aglipay, Birken, Parkin, Loeb et al., Effect of high-dose vitamin D supplementation on upper respiratory tract infection symptom severity in healthy children, Pediatr Infect Dis J
Illescas-Montes, Melguizo-Rodríguez, Ruiz, Vj, Vitamin D and autoimmune diseases, Life Sci
Jetty, Glueck, Wang, Shah, Prince et al., Safety of 50,000-100,000 units of vitamin D3/week in vitamin D-deficient, hypercholesterolemic patients with reversible statin intolerance, North Am J Med Sci
Jimenez-Sousa, Martinez, Medrano, Fernandez-Rodriguez, Resino, Vitamin D in human immunodeficiency virus infection: influence on immunity and disease, Front Immunol
Johansson, Odén, Kanis, Mccloskey, Lorentzon et al., Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden, Osteoporos Int
Jolliffe, Camargo, Jr, Sluyter, Aglipay et al., Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials, Lancet Diabetes Endocrinol
Kasahara, Singh, Noymer, Vitamin D (25OHD) serum seasonality in the United States, PLoS One
Kearns, Alvarez, Tangpricha, Large, single-dose, oral vitamin D supplementation in adult populations: a systematic review, Endocr Pract
Liu, Fang, Wu, Tan, Zhou et al., 1,25-(OH)(2)D(3)/Vitamin D receptor alleviates systemic lupus erythematosus by downregulating Skp2 and upregulating p27, Cell Commun Signal
Lopez, Jorgetti, Caorsi, Ferreira, Palma et al., Epidemiology of renal osteodystrophy in Iberoamerica, Nephrol Dial Transplant
López, Jb, El amplio espectro de la activación del receptor de vitamina D
Malihi, Wu, Lawes, Scragg, Adverse events from large dose vitamin D supplementation taken for one year or longer, J Steroid Biochem Mol Biol
Manson, Cook, Lee, Bassuk, Mora, Vitamin D supplements and prevention of cancer and cardiovascular disease, New Engl J Med
Mansueto, Seidita, Vitale, Gangemi, Iaria et al., Vitamin D deficiency in HIV infection: not only a bone disorder, BioMed Res Int
Manzano, Bierzo, None
Martínez-Alonso, Dusso, Ariza, Nabal, Vitamin D deficiency and its association with fatigue and quality of life in advanced cancer patients under palliative care: a cross-sectional study, Palliat Med
Mazess, Bischoff-Ferrari, Hughes, Vitamin D: bolus is bogus-a narrative review, JBMR Plus
Melamed, Michos, Post, Astor, 25-hydroxyvitamin D levels and the risk of mortality in the general population, Arch Intern Med
Merker, Amsler, Pereira, Bolliger, Tribolet et al., Vitamin D deficiency is highly prevalent in malnourished inpatients and associated with higher mortality: a prospective cohort study, Medicine
Metzger, Stengel, Epidemiology of vitamin D deficiency in chronic kidney disease
Murai, Fernandes, Sales, Pinto, Goessler et al., Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial, Jama
Naves-Diaz, Alvarez-Hernandez, Passlick-Deetjen, Guinsburg, Marelli et al., Oral active vitamin D is associated with improved survival in hemodialysis patients, Kidney Int
Naves-Diaz, Passlick-Deetjen, Guinsburg, Marelli, Fernandez-Martin et al., Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study, Nephrol Dial Transplant
Naves-Díaz, Cabezas-Rodríguez, Barrio-Vázquez, Fernández, Díaz-López et al., Low calcidiol levels and risk of progression of aortic calcification, Osteoporos Int
Nogues, Ovejero, Pineda-Moncusí, Bouillon, Arenas et al., Calcifediol treatment and COVID-19-related outcomes, J Clin Endocrinol Metab
Oddo, Hospital Independencia
Onetto, None
Ortega, The cholecalciferol was friendly donated to HUCA by Gebro Pharma from April to
Paganti, Luciana, Hmc, None
Pal, Banerjee, Bhadada, Shetty, Singh et al., Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis, J Endocrinol Invest
Perge, Boros, Gellér, Osztheimer, Szilágyi et al., Vitamin D deficiency predicts poor clinical outcomes in heart failure patients undergoing cardiac resynchronization therapy, Dis Markers
Pinzone, Rosa, Malaguarnera, Madeddu, Focà et al., Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic, Eur Rev Med Pharmacol Sci
Rodríguez, María, Bierzo, None
Sassi, Tamone, Amelio, Vitamin D: nutrient, hormone, and immunomodulator, Nutrients
Scragg, Stewart, Waayer, Lawes, Toop et al., Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study : a randomized clinical trial, JAMA Cardiol
Sudfeld, Mugusi, Aboud, Nagu, Wang et al., Efficacy of vitamin D(3) supplementation in reducing incidence of pulmonary tuberculosis and mortality among HIV-infected Tanzanian adults initiating antiretroviral therapy: study protocol for a randomized controlled trial, Trials
Sudfeld, Mugusi, Muhihi, Aboud, Nagu et al., Efficacy of vitamin D3 supplementation for the prevention of pulmonary tuberculosis and mortality in HIV: a randomised, double-blind, placebocontrolled trial, Lancet HIV
Tarracina, Laura, Hmc, None
Teresa, Huca, None
Terán, María, Hospital, Bierzo, None
Tukvadze, Sanikidze, Kipiani, Hebbar, Easley et al., High-dose vitamin D3 in adults with pulmonary tuberculosis: a doubleblind randomized controlled trial, Am J Clin Nutr
Vazquez, Huerta-Delgado, Castillo, Villarreal-Calderón, Gonzalez-Gil et al., Correlation of Vitamin D with Inflammatory Cytokines, Atherosclerotic Parameters, and Lifestyle Factors in the Setting of Heart Failure: A 12-Month Follow-Up Study, Int J Mol Sci
Vieth, Chapter 57 -The pharmacology of vitamin D
Vine, Hospital Barros Luco Trudeau -HBLT-and Universidad de Chile -U Chile
Wejse, Gomes, Rabna, Gustafson, Aaby et al., Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial, Am J Respir Crit Care Med
Yang, Ou-Yang, Huang, Low serum vitamin D levels increase the mortality of cardiovascular disease in older adults: a dose-response meta-analysis of prospective studies, Medicine
Zhang, Chen, Yang, Effectiveness of vitamin D supplementation on the outcome of pulmonary tuberculosis treatment in adults: a metaanalysis of randomized controlled trials, Chin Med J
Zhang, Fang, Tang, Jia, Feng et al., Association between vitamin D supplementation and mortality: systematic review and metaanalysis, Bmj
Zittermann, Ernst, Prokop, Fuchs, Dreier et al., Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily, Eur Heart J
Zittermann, Iodice, Pilz, Grant, Bagnardi et al., Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies, Am J Clin Nutr
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop